Intermittent claudication: How should we react to this symptom?

European Heart Journal

Volumn 23, Issue 13, 2002, Pages 1002-1004

  Bounameaux, H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY DISEASE; CARDIOVASCULAR DISEASE; EDITORIAL; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; SYMPTOM; TREATMENT PLANNING; WALKING;

FIBRINOGEN; FIBRINOLYTIC AGENTS; GLYCOSAMINOGLYCANS; HUMANS; INTERMITTENT CLAUDICATION; ITALY; TREATMENT OUTCOME;

EID: 0036660466     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3128     Document Type: Editorial

References (15)

1. Newman AB, Siscovick DS, Manolio TA et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993; 88: 837-45.
2. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
3. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
4. Transatlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease. Inter Angio 2000; 19 (Suppl 1): 1-304.
5. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975-80.
6. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J 2002; 23: 1057-65.
7. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 1988; 26: 569-76.
8. Porter JM, Cutler BS, Lee BY. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.
9. Beebe HG, Dawson DL, Cutler BS et al, A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-50.
10. PACK Claudication Substudy Group. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. Circulation 1989; 80: 1544-87.
11. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989; 62: 681-5.
12. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
13. CAPRIE Study Group. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39.
14. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 2001; 119: 283S-99S.
15. 2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27-34.